Christmas has come early for Karuna Therapeutics’ shareholders. Bristol Myers Squibb has unwrapped a $14 billion deal to acquire the biotech, which sits on the cusp of having the first ...

About Karuna Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.

Karuna Therapeutics, a Boston biotech company working on medicines for psychiatric and neurological conditions, has struck a deal to be acquired by drug giant Bristol Myers Squibb in a $14 billion ...

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year. The company has, as of the fourth quarter, $1.1 billion in cash ...

Drugmaker Bristol Myers BMY1.02%increase; green up pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would ...

Over the past 3 months, 5 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...

(AP Photo/Mel Evans, File) (Mel Evans, AP2005) NEW YORK – Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic ...

Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: These 12 analysts have an average price target of $281.25 versus the current price of ...

It has been about a month since the last earnings report for Karuna Therapeutics, Inc. (KRTX). Shares have added about 8.4% in that time frame, outperforming the S&P 500. Will the recent positive ...

BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric ...

The team behind Karuna Therapeutics, the Boston biotech that was bought by drug giant Bristol Myers Squibb in a $14 billion deal in December, launched another company on Tuesday called Seaport ...

Shares of Karuna Therapeutics Inc. KRTX rocketed 48% into record territory in premarket trading Friday, after the biopharmaceutical company announced an agreement to be bought by Bristol Myers ...